Abstract

BackgroundPrevious data show that serotonin 2C (5-HT2C) and cannabinoid 1 (CB1) receptors have a role in the modulation of sleep–wake cycle. Namely, antagonists on these receptors promoted wakefulness and inhibited rapid eye movement sleep (REMS) in rodents. The interaction of these receptors are also present in other physiological functions, such as the regulation of appetite. Blockade of 5-HT2C receptors modulat the effect of CB1 receptor antagonist, presumably in consecutive or interdependent steps. Here we investigate, whether previous blockade of 5-HT2C receptors can affect CB1 receptor functions in the sleep–wake regulation.ResultsWistar rats were equipped with electroencephalography (EEG) and electromyography (EMG) electrodes. Following the recovery and habituation after surgery, animals were injected intraperitoneally (ip.) with SB-242084, a 5-HT2C receptor antagonist (1.0 mg/kg) at light onset (beginning of passive phase) followed by an injection with AM-251, a CB1 receptor antagonist (5.0 or 10.0 mg/kg, ip.) 10 min later. EEG, EMG and motor activity were analyzed for the subsequent 2 h. Both SB-242084 and AM-251 increased the time spent in active wakefulness, while decreased the time spent in non-REMS and REMS stages in the first 2 h of passive phase. In combination, the effect of the agents were additive, furthermore, statistical analysis did not show any interaction between the effects of these drugs in the modulation of vigilance stages.ConclusionsOur results suggest that 5-HT2C receptor blockade followed by blockade of CB1 receptors evoked additive effect on the regulation of sleep–wake pattern.

Highlights

  • Previous data show that serotonin 2C (5-HT2C) and cannabinoid 1 (­CB1) receptors have a role in the modulation of sleep–wake cycle

  • Based on the above mentioned findings, we aimed to investigate how previous 5-HT2C receptor blockade modifies the effect of a C­ B1 receptor antagonist on the pattern of sleep–wake cycle

  • SB‐242084 and AM‐251 showed additive active wake‐promoting effect With regard to wakefulness, SB-242084 and AM-251 treatments showed additive effect to increase the time spent in active wakefulness (AW)

Read more

Summary

Introduction

Previous data show that serotonin 2C (5-HT2C) and cannabinoid 1 (­CB1) receptors have a role in the modulation of sleep–wake cycle. Antagonists on these receptors promoted wakefulness and inhibited rapid eye movement sleep (REMS) in rodents. The interaction of these receptors are present in other physiological functions, such as the regulation of appetite. Our previous data show that SB-242084, a highly selective 5-HT2C receptor antagonist, promotes wakefulness while decreases both deep slow wave sleep (SWS-2) and REMS [24, 25]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call